Clinical trials: Microcystic Lymphatic Malformation
Lymphatic Malformation
Indocyanine Green Lymphography in Management of Lingual Lymphatic Malformation
To elucidate the application of indocyanine green (ICG) fluorescence angiography in the treatment of childhood tongue cLM (clinically localized malignancy, presumed context here), providing a clearer scientific basis for…
- Trial name
- NCT06755905
- Testing
- ICGL-guided treatment, Conventional Treatment group
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Nanjing Children's Hospital
Microcystic Lymphatic Malformation
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purpose of this study is to assess…
- Trial name
- SELVA (NCT06239480)
- Testing
- QTORIN 3.9% Rapamycin Anhydrous Gel
- Where
- 15 sites in United States
- Volunteers
- 51 people
- Sponsor
- Palvella Therapeutics, Inc.
Lingual Microcystic Lymphatic Malformations
TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN
Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood.
- Trial name
- TOPGUN (NCT04128722)
- Testing
- Sirolimus Oral Liquid Product 1mg/mL
- Where
- 2 sites in France
- Volunteers
- 12 people
- Sponsor
- University Hospital, Tours
Kaposiform Hemangioendotheliomas, Tufted Angioma
Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies
The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved…
- Conditions
- Kaposiform Hemangioendotheliomas, Tufted Angioma, Capillary Venous Lymphatic Malformation, Venous Lymphatic Malformation
- Trial name
- NCT00975819
- Testing
- sirolimus
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Denise Martin Adams
Lymphatic Malformations
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
- Trial name
- EPIK-L1 (NCT05948943)
- Testing
- Alpelisib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
Microcystic Lymphatic Malformation
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
- Trial name
- NCT05050149
- Testing
- PTX-022
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Palvella Therapeutics, Inc.
Microcystic Lymphatic Malformation, Combined Vascular Malformation
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
Lympho-vascular malformations result from errors in embryologic vasculogenesis involving capillaries, veins, arteries, lymphatics, or a combination of these.
- Conditions
- Microcystic Lymphatic Malformation, Combined Vascular Malformation, Vascular Malformations
- Trial name
- NCT06160739
- Testing
- Sirolimus 1Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 10 people
- Sponsor
- Sohag University
Vascular Malformations, Lymphatic Malformation
Topical Sirolimus in Cutaneous Lymphatic Malformations
Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions of children and adults resulting from abnormal embryologic development of lymphatic vessels.
- Trial name
- TOPICAL (NCT03972592)
- Testing
- Topical 0.1% Sirolimus, Topical Vehicle
- Where
- 17 sites in France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Tours
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma
- Trial name
- NCT02978625
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 36 sites in United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)